Cologuard identified as alternative test
October 08, 2015 at 13:06 PM EDT
The
U.S. Preventive Services Task Force identified Exact Sciences Corp. (Nasdaq:
EXAS) Cologuard as an alternative screening test for colorectal cancer
rather than a recommended test sending the stock price plummeting $2.11 to $7.91.